Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 2767Carcinoma, Non-Small-Cell Lung 2265Prostatic Neoplasms 1427Colorectal Neoplasms 1295Neoplasms 1260Multiple Myeloma 1086Lung Neoplasms 1049Neoplasm Metastasis 995Leukemia, Myeloid, Acute 985Lymphoma 900Melanoma 864Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 753Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Squamous Cell Carcinoma of Head and Neck 618Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 598Brain Neoplasms 593Carcinoma, Renal Cell 587Glioblastoma 573Rectal Neoplasms 565Sarcoma 523Myelodysplastic Syndromes 522Lymphoma, Follicular 516

Interventions

durvalumab 1Surgical Procedures, Operative 1Specimen Handling 1Platinum 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Cisplatin 1Capecitabine 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Resectable Intrahepatic Cholangiocarcinoma × Clear all
NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

National Cancer Institute (NCI)

Phase 2 Recruiting
27 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT05265208 2025-08-06

SIROCHO

Center Eugene Marquis

Phase 2 Recruiting
62 enrolled
Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡